Dharmacon, Abbott collaborate on siRNA

FRAMINGHAM (09/24/2003) - Dharmacon Inc. has inked a deal with Abbott Laboratories Inc. to collaborate on an siRNA (small interfering RNA) library covering 4,000 genes to identify potential drug targets for Abbott's key therapeutic areas. "After evaluating the many methodologies available for building this large library, we selected Dharmacon as our partner because their approach of direct chemical synthesis provides a highly effective and cost-efficient method for building a large collection of siRNAs," said Abbott's Stephen Fesik, divisional vice president of cancer research, in a press release. "This siRNA library will allow us to rapidly identify new targets in key therapeutic areas, and Dharmacon's SMART algorithms and 2'-ACE chemistry provide a high success rate for gene silencing." This comes on the heels of other recent Dharmacon deals, including two with Exelixis Inc. and Agilent Technologies Inc.

Join the newsletter!


Sign up to gain exclusive access to email subscriptions, event invitations, competitions, giveaways, and much more.

Membership is free, and your security and privacy remain protected. View our privacy policy before signing up.

Error: Please check your email address.

More about Abbott AustralasiaAgilent TechnologiesAgilent TechnologiesAgilent TechnologiesExelixis

Show Comments